ALNY Alnylam Pharmaceuticals, Inc.
Healthcare$296.34+0.00%OpenMarket Cap: $39.56B
As of 2026-05-26
Valuation
P/E (TTM)
136.16
PEG
0.64
P/B
36.76
P/S
9.26
EV/EBITDA
64.01
DCF Value
$-1,714.43
FCF Yield
1.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
80.9%
Operating Margin
17.5%
Net Margin
13.5%
ROE
98.3%
ROA
11.3%
ROIC
19.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $1.17B | 81.9% | $268.6M | $206.0M | $— | — |
| Q4 null | $1.10B | 75.6% | $131.7M | $186.4M | $— | — |
| FY null | $3.71B | 81.8% | $501.6M | $313.7M | $— | — |
| Q3 null | $1.25B | 84.2% | $368.0M | $251.1M | $— | — |
| Q2 null | $773.7M | 81.5% | $-16.2M | $-66.3M | $— | — |
| Q1 null | $594.2M | 88.0% | $18.1M | $-57.5M | $— | — |
| Q4 null | $593.2M | 82.7% | $-105.2M | $-83.8M | $— | — |
| FY null | $2.25B | 85.6% | $-176.9M | $-278.2M | $— | — |
| Q3 null | $500.9M | 82.9% | $-76.9M | $-111.6M | $— | — |
| Q2 null | $659.8M | 89.6% | $48.6M | $-16.9M | $— | — |
| Q1 null | $494.3M | 86.7% | $-43.4M | $-65.9M | $— | — |
| Q4 2023 | $439.7M | 80.5% | $-116.4M | $-137.9M | $-1.10 | — |